NASDAQ NMS - GLOBAL MARKET · MBRX
+7.55% · +$0.0300 · Vol 342.5K
Market closed · last close 4:00 PM ET · price as of 19:49:28 ET
Moleculin Biotech Inc

Moleculin Biotech Inc

Biotechnology
$0.4560
Card
Relationship Map

Follow $MBRX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $MBRX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
MBRX
Moleculin Biotech Inc
Sat Oct 10 · market closed · Markets closed · resumes Mon 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

36/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Sat Oct 10 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is MBRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading MBRX catalysts
About Moleculin Biotech Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2016
Employees
17
Country
US

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.4199
Day high
$0.4564
Day low
$0.4127
Previous close
$0.4240
52W high
$12.99
-96.49% from high
52W low
$0.3850
1% of range
Market cap
$9M
EPS
$-14.5337
Beta
-0.92
Shares out
20.4M
Volume
342.5K
0.35× rel vol
Avg volume
984.6K
VWAP
$0.4396
Price history computed in-house
1W
-6.33%
1M
-45.05%
3M
-80.00%
1Y
-96.15%
YTD
-86.22%
SMA 50 $0.5796 · below
SMA 200 $2.28 · below
52W position 1%

MBRX overview

Veridion Score
36
Registered · 2026-10-09
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around MBRX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading MBRX Form 4 filings
Public disclosures

Congress activity in MBRX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

MBRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MBRX in this window.
Lobbying spend

MBRX lobbying filings, year to date.

Registered lobbying filings matched to Moleculin Biotech Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MBRX in this window.
Loading news for MBRX
Analyst ratings
Sovereign unlock shows live analyst consensus for MBRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.